{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gauvain K"],"funding":["National Center for Advancing Translational Sciences","American Cancer Society","NCATS NIH HHS","National Cancer Institute","NCI NIH HHS"],"pagination":["28-36"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5909807"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["<h4>Background</h4>Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[<sup>18</sup>F]fluoro-L-phenylalanine (<sup>18</sup>F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using <sup>18</sup>F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors.<h4>Materials and methods</h4>Six patients with recurrent gliomas (5 low-grade, 1 high-grade) planned to undergo treatment with bevacizumab were enrolled. <sup>18</sup>F-FDOPA PET/MRI scans were obtained prior to and 4 weeks following the start of treatment, and these were compared with the clinic"],"journal":["Neuro-oncology practice"],"pubmed_title":["<sup>18</sup>F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors."],"pmcid":["PMC5909807"],"funding_grant_id":["P30 CA091842","UL1 TR002345","K08 CA154790","P30 CA013148","IRG-58-010-56","K08CA154790"],"pubmed_authors":["Ponisio MR","Leeds H","Goyal M","Rubin J","Barone A","McConathy J","Parent E","Grimaldi M","Gauvain K"],"additional_accession":[]},"is_claimable":false,"name":"<sup>18</sup>F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.","description":"<h4>Background</h4>Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[<sup>18</sup>F]fluoro-L-phenylalanine (<sup>18</sup>F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using <sup>18</sup>F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors.<h4>Materials and methods</h4>Six patients with recurrent gliomas (5 low-grade, 1 high-grade) planned to undergo treatment with bevacizumab were enrolled. <sup>18</sup>F-FDOPA PET/MRI scans were obtained prior to and 4 weeks following the start of treatment, and these were compared with the clinic","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Mar","modification":"2025-04-04T14:02:21.618Z","creation":"2019-07-30T07:00:30Z"},"accession":"S-EPMC5909807","cross_references":{"pubmed":["29692922"],"doi":["10.1093/nop/npx008"]}}